The High Commissioner of India, Gaitri Issar Kumar visited Wockhardt UK on Monday 26 July at its pioneering sterile pharmaceutical manufacturing facility in Wrexham, North Wales.
The visit was part of a tour of Indian backed or supported businesses in the United Kingdom, and Wockhardt UK is a subsidiary of global firm Wockhardt Limited based in Mumbai.
As part of her visit, The High Commissioner was provided with a tour of the state-of-the-art vaccine fill finish facility which is currently contracted by the UK Government to manufacture the Oxford/AstraZeneca Covid-19 vaccine until August 2022.
The High Commissioner was also joined by the Indian Honorary Consul for Wales, Raj Aggarwal OBE, RNR.
Her Excellency Mrs. Gaitri Issar Kumar said, “The United Kingdom’s vaccination programme has been a beacon for the world in many ways. It is a matter of great satisfaction that an India-UK collaboration in vaccine manufacture here in the UK has played a vital part in the roll out. The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector”
Dr Habil Khorakiwala, Founder Chairman of Wockhardt emphasised, “The Covid-19 pandemic has been a challenge for all and it needed a concerted effort to overcome. We are proud to be an Indian-led company working in collaboration with the UK government with our innovative international operations in Wales. It is an honour to be recognised for our capability and commitment by the visit from the Indian High Commissioner to the UK, Gaitri.”
Ms Kumar’s visit is the latest one in a series of high-profile VIP attendances at the Wockhardt UK site, HRH Prince Charles and the UK Prime Minister Boris Johnson have also visited Wockhardt UK to witness the fill finish production of the vaccines.
